ArticleiScience2026
Angiotensin II prevents the metabolic but not the transdifferentiating effect of EGF on vascular smooth muscle cells from human female donors.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular smooth muscle cells (VSMCs) are at the center of vascular diseases but studies on VSMCs from human females are rare and the medical need for female-specific vascular research is urgent. VSMCs are simultaneously subjected to paracrine and autocrine mediators, whose effects do not simply add up. For instance, a synergistic crosstalk occurs between the VSMC epidermal growth factor receptor (EGFR), a major transducer of autocrine signals (membrane-derived EGF), and the paracrine angiotensin II (AngII) type 1 receptor (AT1R). Here, we investigated the effects of EGF and AngII on primary human VSMCs from female donors. EGF initiates VSMC transdifferentiation toward a proliferative and inflammatory phenotype and affects glucose and lipid metabolisms. Co-exposure with AngII does not affect the EGF-induced transdifferentiation but counteracts the metabolic effects, independently of AT1R. Activation of the MAS1 receptor by angiotensin 1-7, an AngII-cleavage product, mimicked the AngII effects. Similar EGF-AngII interactions were not observed in male VSMCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.